We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (ADMEC-O)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02196961
Recruitment Status : Active, not recruiting
First Posted : July 22, 2014
Last Update Posted : September 16, 2022
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Prof. Dr. med. Dirk Schadendorf, University Hospital, Essen

Brief Summary:

Primary objective: To estimate the efficacy of adjuvant nivolumab monotherapy in completely resected MCC patients

Primary endpoint: Disease-free survival (DFS) rate evaluated at 12, 24 and 48 months after date of randomization

Secondary Objectives: To describe the safety profile and additional efficacy parameters of the nivolumab treatment in MCC

Secondary endpoints:

  • Adverse events according to CTCAE, Version 4.0 criteria, that are related to the administration of nivolumab
  • Disease-free survival (DFS)
  • Overall survival (OS) and OS rates at 12, 24 and 48 months after randomization

Explorative Endpoints:

  • Distant-metastases-free survival (DMFS) and DMFS rate at 12, 24 and 48 months after randomization
  • Identification and validation of prognostic/predictive biomarkers
  • Quality of life (EORTC QLQ-C30) until 24 months after randomization

Condition or disease Intervention/treatment Phase
Merkel Cell Carcinoma Drug: Nivolumab Phase 2

Detailed Description:

This is an international, open-label, randomized, multicenter phase II study to assess the efficacy of adjuvant nivolumab therapy in completely resected MCC patients. In the initial trial design, the immune modulating treatment was based on CTLA-4 blockade by ipilimumab; however, the advent of PD-1/PD-L1 blockade in the palliative treatment of MCC (presented at AACR, ASCO and ESMO) dramatically changed the treatment environment to an extent that applying treatments other than by PD-1/PD-L1 blockade had become very difficult. Moreover, the side effects of PD-1/PD-L1 blocking are far less frequent than side effects of ipilimumab. Consequently, randomization into the previous Ipilimumab treatment arm A was stopped. New patients will be randomized to nivolumab treatment instead. Patients randomized already into the Ipilimumab-arm will be evaluated descriptively for efficacy and safety. Patients already randomized into the observation arm (arm B) will be evaluated together with the newly randomized arm B-patients. A total of 177 patients with completely resected MCC will be enrolled over a recruitment period of 36 months into this trial, and randomized 2:1 as mentioned above. Patients will be stratified by sex, age, and stage of disease.

Examinations and Follow-up Phase:

The disease will be assessed at baseline, and thereafter every 12 weeks according to the current German guidelines for the management of MCC patients for 24 months after randomization, or until withdrawal of informed consent, lost to follow-up, or death, whichever occurs first. In addition, the patient's quality of life will be evaluated at baseline (pretreatment visit) and every 3 months until 24 months after randomization using a standard questionnaire (EORTC QLQC30).

After 24 months, additional FU visits (or phone calls) will be conducted 6-monthly recording survival and tumor status including subsequent therapies until withdrawal of informed consent, lost to follow-up, death or end of study, whichever occurs first.

End of study is defined as 48 months post LPFV (last patient first visit = date of randomization).

Same methods of assessment (e.g. ultrasonography, CT or MRI scans) used at baseline will be used during follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo®; Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation
Actual Study Start Date : June 2014
Estimated Primary Completion Date : August 31, 2024
Estimated Study Completion Date : August 31, 2024


Arm Intervention/treatment
No Intervention: Observation
After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
Experimental: Nivolumab
After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
Drug: Nivolumab
adjuvant treatment of completely resected Merkel cell carcinoma
Other Name: Opdivo




Primary Outcome Measures :
  1. Disease-free survival (DFS) rate at 12 months [ Time Frame: 1 years post last patient first treatment/randomization ]
    The number of patients alive and free of disease at 12 months after randomization in arm A compared to DFS in arm B.

  2. Disease-free survival (DFS) rate at 24 months [ Time Frame: 2 years post last patient first treatment/randomization ]
    The number of patients alive and free of disease at 24 months after randomization

  3. Disease-free survival (DFS) rate at 48 months [ Time Frame: 4 years post last patient first treatment/randomization ]
    The number of patients alive and free of disease at 48 months after randomization


Secondary Outcome Measures :
  1. Number of adverse events [ Time Frame: 1, 2 and 4 years post last patient first treatment/randomization ]
    Adverse events according to CTCAE, Version 4.0 criteria, that are related to the administration of Ipilimumab

  2. Overall survival rate at 12 months [ Time Frame: 1 year post last patient first treatment/randomization ]
    Overall survival rate at 12 months, defined as the number of patients alive at 12 months after randomization divided by the total number of patients randomized.

  3. Overall survival rate at 24 months [ Time Frame: 2 years post last patient first treatment/randomization ]
    Overall survival rate at 24 months, defined as the number of patients alive at 24 months after randomization divided by the total number of patients randomized.

  4. Overall survival rate at 48 months [ Time Frame: 4 years post last patient first treatment/randomization ]
    Overall survival rate at 48 months, defined as the number of patients alive at 48 months after randomization divided by the total number of patients randomized.

  5. Disease-free survival (DFS) [ Time Frame: 1, 2 and 4 years post last patient first treatment/randomization ]
    Time from randomization to recurrence of tumor

  6. Overall survival (OS) [ Time Frame: 1, 2 and 4 years post last patient first treatment/randomization ]
    Time from randomization to death of patient


Other Outcome Measures:
  1. Distant-metastases-free survival (DMFS) at 12 months after randomization [ Time Frame: 1 year post last patient first treatment/randomization ]
    Number of patients free of distant metastases at 12 months after randomization

  2. Distant-metastases-free survival (DMFS) at 24 months after randomization [ Time Frame: 2 years post last patient first treatment/randomization ]
    Number of patients free of distant metastases at 24 months after randomization

  3. Distant-metastases-free survival (DMFS) at 48 months after randomization [ Time Frame: 4 years post last patient first treatment/randomization ]
    Number of patients free of distant metastases at 48 months after randomization

  4. Identification of prognostic/predictive biomarkers [ Time Frame: 2 and 4 years post last patient first treatment/randomization ]
    Identify and validate prognostic/predictive biomarkers such as immune status, kinetics of the absolute lymphocyte count (ALC), or tumor microenvironment characteristics

  5. Quality of life (EORTC QLQ-C30) until 24 months after randomization [ Time Frame: 2 years post last patient first treatment/randomization ]
    The patient's quality of life will be evaluated at baseline (pretreatment visit) and every 3 months until 24 months after randomization using a standard questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The patient is willing and able to give written informed consent.
  2. Central histological confirmation of diagnosis of Merkel cell carcinoma (MCC).
  3. All MCC manifestations have been completely resected by surgery within 12 weeks before enrolment.
  4. No currently present metastases (as confirmed by standard imaging studies (e.g. suggested by S2k guidelines)).
  5. No previous systemic therapy for MCC.
  6. Required values for initial laboratory tests:

    • WBC ≥ 2000/uL
    • ANC ≥ 1000/uL
    • Platelets ≥ 75 x 103/uL
    • Hemoglobin ≥ 8 g/dL (≥ 80 g/L)
    • Creatinine ≤ 2.0 x ULN
    • AST/ALT ≤ 2.5 x ULN
    • Total Bilirubin ≤ 2.0 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
  7. ECOG performance status 0 or 1.
  8. No active or chronic infection with HIV, Hepatitis B (HBV) or C (HCV).
  9. Men and women, ≥ 18 years of age.
  10. Women of childbearing potential (WOCBP) must be using an adequate method of contraception (Pearl-Index < 1) to avoid pregnancy during treatment phase and for additional 5 months after the last dose of nivolumab, in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not post-menopausal. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before the start of nivolumab.
  11. Men of fathering potential must be using an adequate method of contraception to avoid conception and for 7 months after the last dose of nivolumab in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

  1. Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease requiring systemic steroids (e.g., rheumatoid arthritis, systemic progressive sclerosis, systemic lupus erythematosus, autoimmune vasculitis); autoimmune motor neuropathy.
  2. Other serious illnesses, e.g., serious infections requiring i.v. antibiotics.
  3. The patient is known to be positive for Human Immunodeficiency Virus (HIV) or other chronic infections (HBV, HCV) or has another confirmed or suspected immunosuppressive or immune deficient condition.
  4. Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of nivolumab hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea.
  5. Any non-oncology vaccine therapy for up to 1 month before or after any dose of nivolumab.
  6. A history of prior or current treatment with a T cell potentiating agent (e.g. IL-2, interferon, anti-CTLA-4, anti-CD137, anti-PD1, anti-PD-L1, or anti-OX40 antibody).
  7. Chronic use of immunosuppressive agents or systemic corticosteroids.
  8. Women of childbearing potential (WOCBP), defined above in Section 5.1, who:

    • are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for additional 5 months after the last dose of investigational product
    • have a positive pregnancy test at baseline
    • are pregnant or breastfeeding.
  9. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent or to comply with the trial procedures.
  10. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness.
  11. Men of reproductive potential unwilling to use an adequate method to avoid pregnancy for additional 7 months after the last dose of investigational product.
  12. Use of any investigational or non-registered product (drug or vaccine) other than the study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02196961


Locations
Show Show 20 study locations
Sponsors and Collaborators
Prof. Dr. med. Dirk Schadendorf
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Dirk Schadendorf, Prof. Dr. University Hospital, Essen
Layout table for additonal information
Responsible Party: Prof. Dr. med. Dirk Schadendorf, University Hospital, Essen
ClinicalTrials.gov Identifier: NCT02196961    
Other Study ID Numbers: CA184-205
First Posted: July 22, 2014    Key Record Dates
Last Update Posted: September 16, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Prof. Dr. med. Dirk Schadendorf, University Hospital, Essen:
Merkel cell carcinoma
Adjuvant
Nivolumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Polyomavirus Infections
DNA Virus Infections
Virus Diseases
Infections
Tumor Virus Infections
Carcinoma, Neuroendocrine
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Adenocarcinoma
Neoplasms, Nerve Tissue
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action